GENFIT Assembles Four International Experts for it's Scientific Advisory Board
News Oct 30, 2008
In the field of cardiometabolic diseases and diabetes, the experts are:
Pr Nikolaus Marx, Professor of Medicine and Cardiology at the University of Ulm (Germany), specializes in cardiovascular disease. He received the G.B Morgagni award in 2004.
Pr Markus Stoffel, Professor of Molecular Biology at the EHT in Zurich (Switzerland), specializes in biological and genetic mechanisms that regulate the homeostasis of glucose and lipids.
Pr Arnold von Eckardstein, Professor of Medicine and President of the Institute of Clinical Chemistry of the Zurich University Hospital, is an expert in metabolism of HDL and atherosclerosis.
Pr Gerald F. Watts, Professor of Medicine and Pharmacology at the University of Western Australia (Crawley), specializes in lipid disorders and the metabolic syndrome.
“It’s a great privilege for us to have assembled such a distinguished group of leading experts in our Scientific Advisory Board. Our activities in metabolic and cardiovascular fields and especially our programs in diabetes will greatly benefit from their expertise” stated Professor Bart Staels, President of the Scientific Advisory Board and cofounder of GENFIT. Jean-François Mouney, Chairman and Chief Executive Officer and cofounder of GENFIT, added “We are honored to have these renowned international experts joining our Scientific Advisory Board. Their decision to join our team is recognition of our therapeutic development strategy on an international level and reinforces our scientific approaches to prevent and fight today’s major diseases. Our Scientific Advisory Board will be extended in the coming weeks with experts in neurodegenerative diseases.”
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018